Published in J Acquir Immune Defic Syndr on September 01, 2009
Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81
Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. PLoS Med (2009) 3.18
Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi. PLoS One (2010) 2.36
Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Trends and determinants of survival for over 200 000 patients on antiretroviral treatment in the Botswana National Program: 2002-2013. AIDS (2016) 1.54
Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS (2012) 1.50
Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania. J Acquir Immune Defic Syndr (2013) 1.47
Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One (2012) 1.46
High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One (2013) 1.32
Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. PLoS One (2013) 1.27
Prevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in Rwanda. PLoS One (2013) 1.14
Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010. PLoS One (2014) 1.14
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis (2011) 1.14
Improving data quality and supervision of antiretroviral therapy sites in Malawi: an application of Lot Quality Assurance Sampling. BMC Health Serv Res (2012) 1.08
Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. AIDS (2015) 1.01
Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda. PLoS One (2014) 0.97
High retention among HIV-infected children in Rwanda during scale-up and decentralization of HIV care and treatment programs, 2004 to 2010. Pediatr Infect Dis J (2013) 0.96
Evaluation of the rapid scale-up of collaborative TB/HIV activities in TB facilities in Rwanda, 2005-2009. BMC Public Health (2011) 0.95
Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries. J Acquir Immune Defic Syndr (2015) 0.87
Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women. PLoS One (2011) 0.86
A novel approach to accounting for loss to follow-up when estimating the relationship between CD4 Count at ART initiation and mortality. PLoS One (2013) 0.83
Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program. PLoS One (2014) 0.83
Evaluation of antiretroviral therapy (ART) provision in an early cohort of patients initiating ART in Ghana. Pan Afr Med J (2013) 0.80
Low risk of attrition among adults on antiretroviral therapy in the Rwandan national program: a retrospective cohort analysis of 6, 12, and 18 month outcomes. BMC Public Health (2014) 0.78
Distance from home to study clinic and risk of follow-up interruption in a cohort of HIV-1-discordant couples in Nairobi, Kenya. PLoS One (2012) 0.78
Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc (2016) 0.75
Operating Characteristics of a Tuberculosis Screening Tool for People Living with HIV in Out-Patient HIV Care and Treatment Services, Rwanda. PLoS One (2016) 0.75
Seven year review of retention in HIV care and treatment in federal medical centre Ido-Ekiti. Pan Afr Med J (2015) 0.75
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr (2007) 3.71
Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS (2003) 3.37
Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis (2003) 3.17
Innovations in Rwanda's health system: looking to the future. Lancet (2008) 3.15
Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries. Clin Infect Dis (2013) 2.91
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr (2007) 2.71
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA (2004) 2.31
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis (2009) 2.26
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet (2003) 2.19
Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr (2010) 2.19
Late postnatal transmission of HIV-1 and associated factors. J Infect Dis (2007) 2.11
Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania. BMC Pediatr (2010) 2.09
Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis (2004) 2.06
Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05
Trends in malaria cases, hospital admissions and deaths following scale-up of anti-malarial interventions, 2000-2010, Rwanda. Malar J (2012) 2.01
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr (2011) 1.96
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr (2006) 1.94
Hispanic ethnicity and post-traumatic stress disorder after a disaster: evidence from a general population survey after September 11, 2001. Ann Epidemiol (2004) 1.91
Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2009) 1.82
A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr (2008) 1.81
Strategies for more effective monitoring and evaluation systems in HIV programmatic scale-up in resource-limited settings: Implications for health systems strengthening. J Acquir Immune Defic Syndr (2009) 1.81
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002. J Urban Health (2007) 1.63
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS (2011) 1.59
The impact of breastfeeding on the health of HIV-positive mothers and their children in sub-Saharan Africa. Bull World Health Organ (2006) 1.59
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS (2005) 1.58
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care. AIDS (2014) 1.48
Three surveys of HIV-1 prevalence and risk factors among men working at a sugar estate in Malawi. Sex Transm Dis (2002) 1.47
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg (2009) 1.47
Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One (2012) 1.46
Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda. AIDS (2009) 1.46
Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med (2009) 1.45
Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr Allergy Immunol (2006) 1.44
Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis (2011) 1.42
Reimbursement denial and reversal by health plans at a university hospital. Am J Med (2004) 1.40
Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (2010) 1.37
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning. AIDS Rev (2009) 1.35
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens. BMC Public Health (2010) 1.34
Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes. J Acquir Immune Defic Syndr (2011) 1.32
High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One (2013) 1.32
Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model. Am J Epidemiol (2005) 1.30
High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sex Transm Dis (2011) 1.28
The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring. Epidemiology (2010) 1.26
Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr (2010) 1.25
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol (2012) 1.24
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc (2011) 1.24
TB diagnostic capacity in sub-Saharan African HIV care settings. J Acquir Immune Defic Syndr (2012) 1.22
Colon cancer screening practices in New York City, 2003: results of a large random-digit dialed telephone survey. Cancer (2005) 1.21
Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One (2011) 1.20
Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS (2010) 1.19
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS (2010) 1.19
Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa. PLoS One (2012) 1.19
Correlates of anal intercourse vary by partner type among substance-using women: baseline data from the UNITY study. AIDS Behav (2008) 1.18
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda. J Acquir Immune Defic Syndr (2009) 1.17
Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS (2014) 1.17
Racial/ethnic differences in screening for colon cancer: report from the New York Cancer Project. Ethn Dis (2005) 1.17
Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2008) 1.17
Condom-use decision making in the context of hypothetical pre-exposure prophylaxis efficacy among substance-using men who have sex with men: Project MIX. J Acquir Immune Defic Syndr (2011) 1.15
High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. PLoS One (2011) 1.14
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis (2006) 1.11
PEPFAR programs linked to more deliveries in health facilities by African women who are not infected with HIV. Health Aff (Millwood) (2012) 1.10
Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India. Contraception (2002) 1.10
Scaling up early infant diagnosis of HIV in Rwanda, 2008-2010. J Public Health Policy (2012) 1.09
Monitoring long-lasting insecticidal net (LLIN) durability to validate net serviceable life assumptions, in Rwanda. Malar J (2014) 1.09
Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med (2011) 1.08
Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend (2003) 1.08
Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis (2011) 1.07
Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr (2002) 1.07
Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study. Antivir Ther (2010) 1.04